Clément, Karine
van den Akker, Erica
Argente, Jesús
Bahm, Allison
Chung, Wendy K
Connors, Hillori
De Waele, Kathleen
Farooqi, I Sadaf
Gonneau-Lejeune, Julie
Gordon, Gregory
Kohlsdorf, Katja
Poitou, Christine
Puder, Lia
Swain, James
Stewart, Murray
Yuan, Guojun
Wabitsch, Martin
Kühnen, Peter
Pigeon-Kherchiche, Patricia
Flaus-Furmaniuk, Anna
Bald, Martin
Denzer, Christian
von Schnurbein, Julia
Abawi, Ozair
Blume-Peytavi, Ulrike
Krabusch, Philipp
Mai, Knut
Schnabel, Dirk
Wiegand, Susanna
Flück, Christa E
Schulz, Esther
Voss, Egbert
Bratina, Natasa
Weiss, Katja
Martos-Moreno, Gabriel Á
Danset, Alban
Gougis, Paul
Dubern, Béatrice
Clément, Karine
van den Akker, Erica L.T.
Argente, Jesús
Bahm, Allison L
Chung, Wendy K
Connors, Hillori S
De Waele, Kathleen
Farooqi, Ismaa Sadaf
Gonneau-Lejeune, Julie
Gordon, Gregory A
Poitou, Christine
Puder, Lia
Swain, James M
Stewart, Murray W
Yuan, Goujun
Wabitsch, Martin
Kühnen, Peter
This article is maintained by: Elsevier
Article Title: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Journal Title: The Lancet Diabetes & Endocrinology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S2213-8587(20)30364-8
CrossRef DOI link to the associated document: https://doi.org/10.1016/S2213-8587(20)30366-1
Content Type: article
Copyright: © 2020 Elsevier Ltd. All rights reserved.